首页> 外文期刊>Cell stress & chaperones >Hsp90 blockade modulates bullous pemphigoid IgG-induced IL-8 production by keratinocytes
【24h】

Hsp90 blockade modulates bullous pemphigoid IgG-induced IL-8 production by keratinocytes

机译:Hsp90阻滞调节角质形成细胞大疱性天疱疮IgG诱导的IL-8产生

获取原文
           

摘要

Bullous pemphigoid (BP) is the most common subepidermal autoimmune blistering skin disease characterized by autoantibodies against the hemidesmosomal proteins BP180 and BP230. The cell stress chaperone heat shock protein 90 (Hsp90) has been implicated in inflammatory responses, and recent evidence suggests that it represents a novel treatment target in autoimmune bullous diseases. The aim of the study was to investigate the contribution of Hsp90 to the proinflammatory cytokine production in keratinocytes induced by autoantibodies to BP180 from BP patient serum. HaCaT cells were treated with purified human BP or normal IgG in the absence or presence of the Hsp90 blocker 17-DMAG and effects on viability, interleukin 6 (IL-6) and IL-8 (cytokines critical for BP pathology), NFκB (their major transcription factor), and Hsp70 (marker of effective Hsp90 inhibition and potent negative regulator of inflammatory responses) were investigated. We found that BP IgG stimulated IL-6 and IL-8 release from HaCaT cells and that non-toxic doses of 17-DMAG inhibited this IL-8, but not IL-6 secretion in a dose- and time-dependent fashion. Inhibition of this IL-8 production was also observed at the transcriptional level. In addition, 17-DMAG treatment blunted BP IgG-mediated upregulation of NFκB activity and was associated with Hsp70 induction. This study provides important insights that Hsp90 is involved as crucial regulator in anti-BP180 IgG-induced production of keratinocyte-derived IL-8. By adding to the knowledge of the multimodal anti-inflammatory effects of Hsp90 blockade, our data further support the introduction of Hsp90 inhibitors into the clinical setting for treatment of autoimmune diseases, especially for BP.
机译:大疱性类天疱疮(BP)是最常见的表皮下自身免疫性水疱性皮肤病,其特征在于针对半桥粒蛋白BP180和BP230的自身抗体。细胞应激伴侣热休克蛋白90(Hsp90)与炎症反应有关,最近的证据表明,它代表了自身免疫性大疱性疾病的新型治疗靶标。该研究的目的是研究Hsp90对由BP患者血清产生的针对BP180的自身抗体诱导的角质形成细胞促炎细胞因子产生的贡献。在不存在或存在Hsp90阻断剂17-DMAG的情况下,用纯化的人BP或正常IgG处理HaCaT细胞,并影响其活力,白介素6(IL-6)和IL-8(对BP病理至关重要的细胞因子),NFκB(它们的主要的转录因子)和Hsp70(有效的Hsp90抑制标记和有效的炎症反应负调节剂)进行了研究。我们发现BP IgG刺激了HaCaT细胞的IL-6和IL-8释放,并且无毒剂量的17-DMAG以剂量和时间依赖性的方式抑制了该IL-8,但没有抑制IL-6的分泌。在转录水平上也观察到该IL-8产生的抑制。另外,17-DMAG处理减弱了BP IgG介导的NFκB活性上调,并与Hsp70诱导有关。这项研究提供了重要的见解,认为Hsp90作为抗BP180 IgG诱导的角质形成细胞衍生IL-8产生中的关键调控因子。通过增加对Hsp90阻断的多峰抗炎作用的认识,我们的数据进一步支持将Hsp90抑制剂引入临床环境,以治疗自身免疫性疾病,特别是对BP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号